This article first appeared on GuruFocus .
-
Total Revenue:$46.5 million in Q2 2026, up 29% quarter-over-quarter and roughly 3.9 times from a year ago.
-
IM8 Revenue:$45 million in Q2, up 33% sequentially, with a 65% gross margin.
-
Gross Profit:$30.2 million in Q2, at a 65% gross margin, about 3 full points better than the same period a year ago.
-
Fixed Operating Costs:$8.8 million in Q2, representing 19% of sales, up 14% versus prior quarter but 2.3 times greater than a year ago.
-
Contribution Profit:$21.4 million in Q2, at 46% of sales, a 16% better margin than one year ago.
-
Acquisition Marketing Spend:$36.2 million in Q2, representing 78% of sales.
-
Adjusted EBITDA:Negative $19 million in Q2, a byproduct of marketing spend.
-
Net Loss:$9 million for Q2, or $0.52 per share, down 45% from the same period a year ago when the loss per share was $0.94.
-
July Revenue:$20.9 million in July, the strongest month in company history, at an annualized run rate of roughly $251 million.
-
July Gross Margin:64% on July revenue.
-
July Contribution Profit:$10.4 million in July, at a 49% contribution margin.
-
July Adjusted EBITDA:Negative $2.4 million loss, or negative 11% adjusted EBITDA margin.
-
New Customers Acquired (Q2):118,000 new customers, 98% better than prior quarter, with CACs flat to slightly down at negative 1%.
-
New Customers Acquired (July):47,373 customers at a customer acquisition cost of about $239, down roughly 21% from Q2.
-
Cash and Current Financial Assets:$109.4 million on the balance sheet.
-
Active Subscribers:140,000 active subscribers.
-
Full Year 2026 Revenue Guidance:Raised to $220 million to $230 million, with IM8 contributing $215 million to $222 million.
-
2027 Revenue Guidance:Initiating $400 million or more.
-
Q3 2026 Guidance:$61.5 million to $62.5 million on IM8 revenue, or $63 million to $64 million on the Prenetics parent.
-
Q4 2026 Implied Revenue:$81.2 million, which would put the company at the top of its guidance.
Release Date: August 18, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Prenetics Global Ltd ( NASDAQ:PRE ) achieved its first month of positive consolidated adjusted free cash flow in July 2026, crossing a key profitability milestone ahead of schedule.
-
The company delivered its sixth consecutive record quarter, with Q2 2026 revenue of $46.5 million, up 29% sequentially and 3.9x year-over-year, beating its own guidance.
-
Customer acquisition costs (CAC) fell 21% in July to $239, even as the company acquired a record 47,373 new customers, demonstrating improving marketing efficiency.
-
Prenetics Global Ltd ( NASDAQ:PRE ) raised its full-year 2026 revenue guidance to $220-$230 million and initiated 2027 guidance of $400 million or more, driven by a strong recurring revenue base.
-
The company secured a $1 billion funding commitment from General Catalyst, which will fund 70% of its acquisition marketing spend, removing a major cash constraint on growth.
-
Prenetics Global Ltd ( NASDAQ:PRE ) is expanding its product pipeline with IM8 Hydration and premium gummies, targeting large markets ($37 billion and $25 billion respectively), backed by ongoing clinical trials including one at the Mayo Clinic.
-
The company's AI-native organizational structure allows it to scale efficiently, with revenue per employee exceeding $3 million and fixed operating costs falling 21% quarter-over-quarter.
-
Independent data shows Prenetics Global Ltd ( NASDAQ:PRE ) has superior customer retention (14.2% at month 20) compared to competitors like AG1 and Thorne, and it is gaining significant market share.
-
The company maintains a strong balance sheet with $109.4 million in cash and current financial assets, and has reduced its share count through a $40 million buyback.
-
Prenetics Global Ltd ( NASDAQ:PRE ) is expanding its board with the addition of veteran consumer analyst Caroline Levy, adding significant industry expertise and credibility.
Negative Points
-
Prenetics Global Ltd ( NASDAQ:PRE ) reported a net loss of $9 million for Q2 2026, and while improving, the company is still not profitable on a GAAP basis.
-
The company's adjusted EBITDA remained negative at -$19 million for Q2 2026, reflecting heavy investment in customer acquisition that has yet to fully pay off.
-
The company's guidance for 2027 of $400 million or more is ambitious and relies on continued rapid growth, which may be difficult to sustain as the base becomes larger.
-
Prenetics Global Ltd ( NASDAQ:PRE ) faces intense competition in the supplement space from established brands like AG1, Thorne, and others, which could pressure market share and pricing.
-
The company's growth is heavily dependent on a single product line (IM8 Daily Essentials), and the success of new product launches (hydration, gummies) is not yet proven.
-
The company's customer acquisition costs, while improving, remain high at $239 per customer, and the long-term payback period for these investments is still being validated.
-
Prenetics Global Ltd ( NASDAQ:PRE ) is not currently in large markets like China and India, limiting its total addressable market in the near term.
-
The company's reliance on the General Catalyst funding facility introduces financial risk, as the terms and repayment obligations could impact future cash flows.
-
The company's stock price is volatile, and the potential dilution from warrants (2.36 million at $18 strike) could pressure shareholder value if the stock price rises.
-
The company's expansion into new product categories and geographies will require significant investment and execution, which could strain its AI-native, lean organizational structure.
Q & A Highlights
Q: How should we think about the marketing spend in the second half of the year, especially as it bridges to the updated adjusted EBITDA loss, given the General Catalyst funding removes the cash constraint? A: Brian Rosin (CFO, IM8) stated that the second-half marketing spend as a percentage of revenue will likely be in line with Q2, possibly slightly more favorable, but not materially different. He noted that while they do not expect the July customer acquisition efficiency to continue, they anticipate a little more leverage on the marketing line versus Q2.
Q: As quarterly subscriptions become a larger share of the business, where do you see sustainable gross margins going forward? A: Brian Rosin (CFO, IM8) explained that the quarterly subscription duration is more favorable for margins. As the mix shifts more heavily towards quarterly subscriptions, he expects at least a few points of additional margin. He also highlighted future economies of scale in supply chain, third-party logistics, postage, freight, and product costs, which should further expand gross margins into 2027.
Q: What drove the acceleration in revenue and improved CAC in July, and have you seen any normalization in August? A: Danny Yeung (CEO) attributed July's performance to a spillover effect from the doubled Q2 spend, a stronger brand with increased word-of-mouth, and a halo effect from ambassador signings like Giannis and Inter Miami. He noted that August is too early to comment on CAC trends, but the company is seeing continued momentum.
Q: Can you provide more detail on the new product launches (hydration and gummies) and the potential attach rate with your current subscriber base? A: Danny Yeung (CEO) revealed that post-purchase surveys showed hydration and gummies were the top requested products from existing customers, with more than 20% of the current customer base asking for them. He emphasized that these products are complementary, not competitive, and will help cross-sell and upsell the hero products (Essentials and Longevity). He also noted that 20-30% of current customers are parents, making kids' gummies a natural fit.
Q: How has the competitive landscape evolved, and are new customers coming from competitors or new entrants? A: Danny Yeung (CEO) cited third-party data showing IM8 has taken significant market share from top players, with IM8 growing 2,500% since launch while AG1 declined 36% and Gruons declined 50%. He highlighted that IM8 has the highest average order value (~$180) in the supplement category, with over 50% of customers having a household income above $150,000. He estimated that 20-30% of new customers come from competitors, while others are consolidating multiple supplements into one product.
Q: Can you talk about the TikTok Shop and social commerce efforts, and how you prioritize revenue through your own store versus off-store channels? A: Danny Yeung (CEO) stated that IM8 is built on a direct-to-consumer model, with roughly 95% of transactions on their own website and 5% on Amazon. This design allows them to capture customer email information and create a better experience. While they are experimenting with TikTok and AppLovin, the majority of transactions remain on their website, and they see significant growth opportunities in DTC.
Q: Beyond getting on physician radars, what are your plans to leverage the science for future products or partnerships, and what are the expected readouts from the studies? A: Danny Yeung (CEO) emphasized that science is core to the brand's foundation. He expects results from the longevity and gut health trials by Q1 2027, and the Mayo Clinic trial by Q2 or Q3 2027. He noted these are multimillion-dollar trials that form part of the company's moat, and while results are uncertain, they are confident given the quality of ingredients and the scientific advisory board.
Q: With Caroline Levy's background in beverages, are there thoughts around form factor expansions and potential retail sales, particularly for the upcoming hydration product? A: Danny Yeung (CEO) acknowledged that retail is a possibility in the future, but the current focus is on launching stick powders for hydration and gummies. He emphasized a deliberate approach, not rushing into new categories, and will evaluate other form factors after these launches.
Q: Do the guided adjusted free cash flow and adjusted EBITDA both add back the General Catalyst funding? A: Brian Rosin (CFO, IM8) confirmed that both metrics add back the General Catalyst funding. He clarified that on the cash flow statement, it will be presented as cash from financing, but since it is real cash funding the largest part of the P&L, they present an adjusted free cash flow view that assumes operating cash flow plus proceeds from General Catalyst net of repayments. The funding does not impact EBITDA guidance, only cash flow.
Q: How are you thinking about distribution channels, international opportunities, and the competitive moat? Why would another brand not copy what you are doing? A: Danny Yeung (CEO) stated that IM8 is 100% DTC and sees no slowdown in online growth, with no need for retail for the next 24-36 months. The company is in 46 countries, excluding China and India, with China potentially being explored in 18-24 months. Regarding the moat, he highlighted the combination of science, brand, General Catalyst funding, subscription engine, AI-native organization, and founder ownership as difficult to copy. He also noted that P&G's acquisition of Thorne at nearly 6x revenue validates the sector, but IM8 is building a generational health company, not to be acquired.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
